Oct. 30 at 2:24 PM
TD Cowen⬆️the price target on
$OCUL to
$20 from
$14, reiterated at Buy, and said, 'Axpaxli Is Uniquely Poised For Large Potential In Retinal Disease' after its🗣️w/ KOLs.
$EYPT $FDMT $REGN $RGNX
TD Cowen said in its note:
We and KOLs are highly optimistic about Axpaxli's robust use in wAMD with a differentiated superiority label, and our
$1B peak estimate is conservative.
The additional NPDR opportunity is underappreciated, as Axpaxli could invigorate the 10x larger market where KOLs estimate ~30% use.
As such, we are adding a very conservative
$800MM peak NPDR estimate, resulting in a new DCF-based PT of
$20.
